Day: May 4, 2020

Reported production sales volume of 2.9 million barrels of oil equivalent (“MMBoe”) for the first quarter of 2020, above the high end of guidance Oil production sales volume of 1.6 million barrels of oil (“MMBbls”) for the first quarter of 2020; 55% of total equivalent production sales volume and above the high end of guidance First quarter of 2020 capital expenditures totaled $70 million, below the low end of guidance Reduced bank debt by $45 million or 32% during the first quarter of 2020; prioritizing the preservation of balance sheet and liquidity and free cash flow generation Strong hedge position insulates 2020 and 2021 cash flow against fluctuations in crude prices; current mark-to-market value of approximately $170 million See COVID-19 disclosures on Page 7DENVER, May 04, 2020 (GLOBE NEWSWIRE) — HighPoint...

TAMPA, Fla., May 04, 2020 (GLOBE NEWSWIRE) — Sykes Enterprises, Incorporated (“SYKES” or the “Company”) (NASDAQ: SYKE), a leading full life cycle provider of global customer engagement services, multichannel demand generation and digital transformation, has released its financial results for the first-quarter ended March 31, 2020. The first-quarter 2020 financial results can be viewed at either www.sykes.com, under the “Investor News” section, or using the following link: http://investor.sykes.com/company/investors/investor-news/default.aspx.Forward-Looking StatementsThis press release may contain “forward-looking statements,” including SYKES’ estimates of its future business outlook, prospects or financial results. Statements regarding SYKES’ objectives, expectations, intentions, beliefs or strategies, or statements containing...

DUBLIN, Ireland, May 04, 2020 (GLOBE NEWSWIRE) — Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in patients with narcolepsy, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, May 11, 2020, to provide a corporate update and discuss the Company’s financial results for the first quarter ended March 31, 2020.To access the conference call, investors are invited to dial 877-407-9716 (U.S. and Canada) or 201-493-6779 (international). The conference ID number is 13703221. A live audio webcast can be accessed by visiting the investor relations section of the Company’s website, www.avadel.com. A replay of the webcast will be archived on...

Annual recurring revenues of $220.5 million, representing growth of 59% over Q1 2019Subscription revenues mix of 98%, compared to 31% in Q1 2019NEW YORK, May 04, 2020 (GLOBE NEWSWIRE) — Varonis Systems, Inc. (Nasdaq: VRNS), a pioneer in data security and analytics, today announced results for the first quarter ended March 31, 2020.“We are operating in unprecedented times, requiring us to plan carefully, act decisively and remain nimble, the same skills that we used to successfully transition Varonis to a subscription model over the last year,” said Yaki Faitelson, Varonis CEO. “The disruption that COVID-19 has caused to businesses globally is undeniable. However, at the same time the associated risks to our customers – specifically, the confluence of a distributed workforce, the elevated use of VPNs and unsecured...

DALLAS and FORT WORTH, Texas, May 04, 2020 (GLOBE NEWSWIRE) — Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that it will report its first quarter 2020 financial results at the closing of U.S. financial markets on Monday, May 11, 2020. Neos management will host a conference call and live audio webcast to discuss these results and provide a company update at 5:00 p.m. ET that same day.The live call may be accessed by dialing (877) 388-8985 for domestic calls, or +1 (562) 912-2654 for international callers, and referencing conference ID number 1099917. A live audio webcast for the conference call will be available on the Investor Relations page of the company’s website at http://investors.neostx.com/ and will be...

BOULDER, Colo., May 04, 2020 (GLOBE NEWSWIRE) — Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that it will report its first quarter 2020 financial results after the close of the U.S. financial markets on Wednesday, May 13, 2020. Brickell’s management will host a conference call at 4:30 p.m. ET to discuss the financial results and recent corporate highlights.The dial-in number for the conference call is 1-855-327-6837 for domestic participants and 1-631-891-4304 for international participants, with Conference ID #10009475.  A live webcast of the conference call can be accessed through the “Investors” tab on the Brickell Biotech website at http://www.brickellbio.com/. ...

SANTA CLARA, Calif., May 04, 2020 (GLOBE NEWSWIRE) — SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter ended March 31, 2020.Recent HighlightsRevenue of $16.8 million for the first quarter 2020, representing a 12% increase over the corresponding period in 2019U.S. revenue of $15.3 million for the first quarter 2020, representing a 14% increase over the corresponding period in 2019Received FDA 510(k) clearance for an expanded indication for the iFuse Implant System to support the Company’s trauma programObtained positive coverage by Health Alliance Plan, a commercial payor in Michigan“Our SI-BONE team has shown tremendous efforts and strength through these difficult times. I am incredibly proud to be...